New rabies vaccine shows promise in preventing deadly infection

NCT ID NCT04594551

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 201 healthy adults in Thailand. Participants received the vaccine along with rabies antibodies, mimicking post-exposure treatment. The study measured immune response and safety, finding that the vaccine triggered protective antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Purified vero rabies vaccine - serum free (VRVg-2)

What this could lead to

If successful, this could provide a safer, effective rabies vaccine option for post-exposure prevention.

What could go wrong

This is a completed Phase 3 trial in healthy adults, not actual rabies patients. Real-world effectiveness and safety in infected individuals may differ.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES (HEALTHY VOLUNTEERS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational site number 7640001

    Bangkok, 10400, Thailand

  • Investigational site number 7640002

    Bangkok, 10330, Thailand

  • Investigational site number 7640003

    Bangkok, 10700, Thailand